Early Alzheimer’s Detection Marks Significant Breakthroughs for Families

If you have an extended family or more than two friends, you likely have seen the devastating reality that is Alzheimer’s. Our loved ones no longer recognize us or share the memories accumulated over a lifetime. It’s often said that when you have a loved with with Alzheimer’s, you lose them twice.

To make everything more heartbreaking, it’s hard to know if you or your loved one actually has Alzheimer’s until after you have dies, via autopsy. Are some of those memory lapses perfectly normal or do you have this disease? Early changes get written off as “senior moments” or normal aging. Most people don’t receive a diagnosis until they’ve reached mild dementia—already the third stage of the disease. This timing matters enormously, because researchers believe catching Alzheimer’s earlier opens doors to treatments that might slow its relentless advance and help protect remaining brain function.

While brain imaging, cognitive testing, and family history helped piece together the puzzle, a new FDA-approved blood test is changing how we approach early detection.

Alzheimer’s represents far more than typical memory lapses that come with aging. This progressive brain disease systematically dismantles cognitive function and independence. The numbers tell a sobering story—the Alzheimer’s Association notes it kills more people each year than breast and prostate cancer combined. With nearly 7 million Americans currently living with the disease, and projections pointing toward 13 million by 2050, we’re facing a growing crisis.

How Diagnosis Has Worked

The traditional diagnostic journey was neither simple nor reliable. MRI scans could show brain shrinkage or activity changes, but these findings rarely provided clear answers. Spinal taps to test cerebrospinal fluid offered another avenue, though results varied significantly between labs and testing methods.
More sophisticated options like PET scans can spot the telltale amyloid plaques and tau tangles that characterize Alzheimer’s, delivering better accuracy.

However, these scans require expensive equipment and specialized expertise, making them second-line tests used after other approaches prove inconclusive.

The Blood Test Breakthrough

Researchers have been working toward simpler solutions. The University of Washington developed an early blood test called SOBA that could detect beta-amyloid oligomers—tiny protein clusters thought to kickstart the disease process.

Now the FDA has approved a blood test from Fujirebio Diagnostics called the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio. This test measures specific Alzheimer’s proteins circulating in blood. The FDA’s approval came after clinical studies showed impressive results:

Among people who tested positive, 92% actually had amyloid plaques confirmed through PET scans or spinal fluid tests. Among those who tested negative, 97% truly didn’t have these plaques

The beauty lies in its simplicity—just a blood draw, no spinal taps or complex imaging required. This makes it practical for routine use in doctors’ offices.

That said, this test won’t replace clinical judgment. Doctors still need to evaluate the complete picture before making an Alzheimer’s diagnosis. Like any test, false positives and negatives can occur. But as part of a comprehensive evaluation, this blood test represents a major step forward in catching Alzheimer’s earlier and more reliably.

SB Note: From time to time, we see clinical studies that we feel strongly we need to help push out on StyleBlueprint.com. In these circumstances, we do rely on AI to help make these studies more accessible. We do fact-check to ensure accuracy and that no “AI hallucinations” are part of our coverage.